BioSpace News Archive

Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), a clinical-stage biotech company developing treatments for orphan retinal diseases, today announced that it has entered a strategic development

RTI Surgical, an industry leading contract development and manufacturing organization, serving the regenerative medicine industry, announced that it has completed its previously announced acquisition of Cook Biotech Incorporated.

MaximBio is pleased to announce that it has been granted a second follow-on award from the National Institutes of Health Rapid Acceleration of Diagnostics Tech program for the continued development of its revolutionary FiarFly™ reader and COVID-19 & Flu A/B multiplex test.

[01-February-2024] Avation’s Vivally® System, the only FDA-cleared, non-invasive, closed-loop, at-home wearable, changes the way urinary incontinence and urgency caused by overactive bladder syndrome is treated COLUMBUS, Ohio , Feb. 1, 2024 /PRNewswire/ -- Avation Medical , an innovative neuromodulation and digital health company with a mission to make wearable peripheral neuromodula

Vaxcyte, Inc. announced that Company management will participate in a fireside chat at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference in New York on Thursday, February 8, 2024 at 10:00 a.m. ET / 7:00 a.m. PT.

X4 Pharmaceuticals, a company driven to improve the lives of people with rare diseases of the immune system, announced that, effective on January 31, 2024, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan.

Relay Therapeutics, Inc. (Nasdaq: RLAY) today announced that management will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on Thursday, February 8, 2024 at 10:30 a.m. ET.

Revolution Medicines, Inc. announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will be a featured speaker at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference and the TD Cowen 44th Annual Health Care Conference.

Renexxion Ireland Limited (“Renexxion”), a private biopharmaceutical company committed to delivering innovative drugs to patients with high unmet need in gastrointestinal (“GI”) disorders, announced today that the company will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Tuesday, February 13th, 2024.

DELFI Diagnostics, Inc., a developer of accessible blood-based tests that deliver a new way to enhance cancer detection, today announced availability of the company’s fragmentome-based research use only (RUO) cancer monitoring assay.